HCM
CRSP icon

Hollencrest Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Hollencrest Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5K Sell
375
-937
-71% -$49.4K ﹤0.01% 724
2026
Q1 		$62.4K Buy
1,312
+937
+250% +$49.4K ﹤0.01% 516
2025
Q4 		$19.7K Sell
375
-250
-40% -$15K ﹤0.01% 714
2025
Q3 		$40.5K Hold
625
– – ﹤0.01% 588
2025
Q2 		$30.4K Hold
625
– – ﹤0.01% 597
2025
Q1 		$21.3K Hold
625
– – ﹤0.01% 661
2024
Q4 		$24.6K Hold
625
– – ﹤0.01% 652
2024
Q3 		$29.4K Hold
625
– – ﹤0.01% 599
2024
Q2 		$33.8K Hold
625
– – ﹤0.01% 580
2024
Q1 		$42.6K Hold
625
– – ﹤0.01% 511
2023
Q4 		$39.1K Hold
625
– – ﹤0.01% 521
2023
Q3 		$28.4K Hold
625
– – ﹤0.01% 561
2023
Q2 		$35.1K Hold
625
– – ﹤0.01% 548
2023
Q1 		$28.3K Hold
625
– – ﹤0.01% 570
2022
Q4 		$25.4K Buy
+625
New +$33.2K ﹤0.01% 564

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hollencrest Capital Management's CRSP Position: Q2 2026 in Review

Hollencrest Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 71% in Q2 2026, selling an estimated $49.4K and leaving 375 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Hollencrest Capital Management first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. The position peaked at $62.4K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hollencrest Capital Management held 375 shares of CRISPR Therapeutics worth $20.5K as of Q2 2026.
  • Hollencrest Capital Management sold 937 CRISPR Therapeutics shares in Q2 2026, an estimated $49.4K.
  • CRISPR Therapeutics made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #724 holding.
  • Hollencrest Capital Management first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Hollencrest Capital Management's CRISPR Therapeutics position peaked at $62.4K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.